SGLT2 Inhibitors and the Risk of Contrast-Associated Nephropathy Following Angiographic Intervention: Contradictory...

Area of Science:

• Nephrology
• Cardiology
• Radiology

Background:

• Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are known to slow chronic kidney disease (CKD) progression and reduce acute kidney injury (AKI) risk.
• Emerging evidence suggests SGLT2is might decrease the incidence of contrast-associated nephropathy (CAN) after contrast-enhanced procedures.
• However, potential risks and confounding factors require careful consideration.

Purpose of the Study:

• To critically evaluate the proposed renoprotective effects of SGLT2is against CAN.
• To highlight potential pitfalls and confounders in existing studies on SGLT2is and CAN.
• To emphasize the need for further research, particularly in high-risk patient populations.

Main Methods:

• Review of existing clinical studies and literature concerning SGLT2is and CAN.
• Analysis of the physiological mechanisms by which SGLT2is and contrast media interact in the kidney.
• Identification of patient subgroups at higher risk for adverse events.

Main Results:

• Existing studies suggest a potential benefit of SGLT2is in preventing CAN.
• Concerns exist regarding potential synergistic medullary hypoxia induced by SGLT2is and contrast media in diabetic kidneys.
• High-risk patients with advanced CKD and hemodynamic instability may be particularly vulnerable.

Conclusions:

• Caution is warranted when interpreting the safety and efficacy of SGLT2is for preventing CAN.
• The combination of SGLT2is and contrast media could potentially exacerbate medullary hypoxic damage.
• Further studies are essential to clarify the actual risk-benefit profile of SGLT2is in the context of contrast-enhanced procedures, especially in high-risk individuals.